Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration Business Wire - Fri Jun 17, 2022

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application...

SRRA : 54.99 (+0.04%)
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting Business Wire - Thu May 26, 2022

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the...

SRRA : 54.99 (+0.04%)
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting Business Wire - Thu May 12, 2022

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the...

SRRA : 54.99 (+0.04%)
Sierra Oncology Reports First Quarter 2022 Results Business Wire - Fri May 6, 2022

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results...

SRRA : 54.99 (+0.04%)
Stocks-Money-Rates - Business Section of Newspaper -E7RLgUjjazc-unsplash
Stocks Lower as U.S. PPI Surges to a Record Barchart - Wed Apr 13, 2022

Morning Markets June S&P 500 futures this morning are down -0.05%. U.S. stock index futures gave up overnight gains and are modestly lower after U.S. March producer prices rose more than expected at a...

ALK : 36.96 (-4.12%)
UAL : 90.07 (-2.65%)
HLMN : 7.50 (-4.58%)
JPM : 307.65 (-1.54%)
KMX : 36.88 (-4.28%)
SRRA : 54.99 (+0.04%)
AAL : 11.81 (-0.25%)
LUV : 38.35 (-1.06%)
FAST : 44.88 (-0.07%)
NSTG : 0.1053 (-37.43%)
DAL : 68.50 (-0.70%)

Barchart Exclusives

This Blue-Chip Dividend Stock Is Becoming an AI Star Barchart - Mon May 4, 6:30PM CDT
Caterpillar is increasingly being treated as an AI‑infrastructure play, with data‑center and hyperscale power demand now a visible, incremental growth driver layered on top of its core construction, mining, and energy cycles rather than a one‑off theme. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.